A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

This study is testing a new experimental medicine called EP0031 (Lunbotinib) to see if it is safe and effective for treating a specific type of advanced lung cancer. It is designed to help patients whose cancer has a specific genetic change known as a 'RET alteration'.

You may be eligible if you are 18 or older and have non-small cell lung cancer with a RET alteration that is measurable on scans. You must also be able to perform daily activities independently and be in stable enough health to follow the study schedule.

Participants will receive either the new drug alone or in combination with standard cancer treatments like chemotherapy. Throughout the study, you will have regular check-ups and medical scans to monitor how the treatment is working and ensure you are feeling well.

This study is currently recruiting new participants and is taking place at medical centers in Los Angeles and Stanford, California, as well as in Washington, D.C.